CJC 1295/Ipamorelin Blend 5/5MG

Buy CJC 1295/Ipamorelin Blend 5/5MG in Australia | CJC 1295/Ipamorelin Blend 5/5MG for sale 

CJC-1295 with DAC is a synthetic peptide developed to stimulate the secretion of growth hormone (GH) from the pituitary gland. It is a modified version of the endogenous growth hormone-releasing hormone (GHRH), featuring a peptide sequence of 30 amino acids linked to a drug affinity complex (DAC). This modification enhances the peptide’s stability and half-life, thereby prolonging its efficacy in stimulating GH release.

What is Ipamorelin?

Ipamorelin is a synthetic peptide belonging to the class of growth hormone secretagogues (GHSs), designed to stimulate the secretion of growth hormone (GH) from the pituitary gland. It consists of a pentapeptide sequence, comprising five amino acids (alanine-aminosine-tryptophan-lysine-phenylalanine). Ipamorelin lacks additional modifications like DAC and is known for its ability to induce a transient elevation in GH levels.

Structure of CJC-1295 with DAC

CJC-1295 with DAC is composed of a peptide sequence derived from growth hormone-releasing hormone (GHRH), featuring 30 amino acids arranged in a specific sequence. Additionally, it contains a drug affinity complex (DAC), a modification involving the attachment of a fatty acid chain to the peptide sequence. This complex enhances the peptide’s stability and half-life, contributing to its prolonged efficacy in stimulating GH secretion.

Structure of Ipamorelin

Ipamorelin is a relatively simple peptide consisting of five amino acids arranged in a specific sequence: alanine-aminosine-tryptophan-lysine-phenylalanine. Unlike CJC-1295 with DAC, Ipamorelin does not contain additional modifications like DAC. Its straightforward structure facilitates its synthesis and administration as a therapeutic agent for stimulating GH secretion.

Mechanism of Action for CJC-1295 with DAC

CJC-1295 with DAC exerts its effects by binding to the growth hormone-releasing hormone receptor (GHRHR) located on somatotroph cells within the anterior pituitary gland. This interaction triggers intracellular signaling pathways, including cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathways, leading to the transcription and secretion of growth hormone (GH) from somatotroph cells. Additionally, CJC-1295 with DAC enhances the pulsatile release of GH by increasing the amplitude and frequency of GH pulses, resulting in a more physiologically relevant pattern of GH secretion.

Mechanism of Action for Ipamorelin

Ipamorelin acts by binding to the growth hormone secretagogue receptor (GHSR), also known as the ghrelin receptor, located on somatotroph cells within the pituitary gland. Upon binding, Ipamorelin triggers signaling cascades involving phospholipase C (PLC) and protein kinase C (PKC) pathways, leading to the release of growth hormone (GH) from somatotroph cells. Notably, Ipamorelin primarily stimulates the pulsatile release of GH, resulting in a transient elevation in GH levels.

Synergistic Effects of CJC-1295 with DAC and Ipamorelin

When together, CJC-1295 with DAC and Ipamorelin may exhibit synergistic effects in stimulating the secretion of growth hormone (GH). CJC-1295 with DAC enhances the pulsatile release of GH and promotes a more sustained elevation in GH levels, while Ipamorelin induces a transient spike in GH secretion. The combination of these peptides may offer a more comprehensive and physiologically relevant stimulation of GH secretion, potentially enhancing their therapeutic efficacy in various contexts.

CJC-1295 Normalizes Growth in Mouse Model

In animal studies involving GHRH knockout (GHRHKO) mice, the efficacy of CJC-1295, a synthetic GHRH analog, was evaluated for its impact on growth and body composition. Despite the short half-life of GHRH, CJC-1295, which binds to endogenous albumin, extended its duration of action. GHRHKO mice treated with daily doses of CJC-1295 exhibited normal body weight and length.

Those treated every 48 and 72 hours showed increased body weight and length compared to placebo-treated mice but did not fully normalize growth. However, mice treated every 24 and 48 hours maintained normal femur and tibia length. Additionally, relative lean mass and subcutaneous fat mass were normal across all treated groups. 1

CJC-1295 administration led to increased total pituitary RNA and GH mRNA levels, suggesting somatotroph cell proliferation, as confirmed by immunohistochemistry. Overall, once-daily administration of CJC-1295 maintained normal body composition and growth in GHRHKO mice, though its effectiveness decreased with less frequent dosing. 1

Ipamorelin Induces Longitudinal Bone Growth in Rat Model

In a detailed study involving adult female rats, researchers examined the effects of ipamorelin, a synthetic pentapeptide known for its specific GH-releasing properties. The study focused on several key factors: longitudinal bone growth rate (LGR), body weight (BW) changes, and the release of growth hormone (GH).

Throughout the experiment, ipamorelin was administered to the rats via subcutaneous injections, given three times daily for a duration of 15 days. The doses of ipamorelin used varied.

Results from the study revealed that ipamorelin exhibited a dose-dependent impact on the longitudinal bone growth rate. Rats receiving ipamorelin showed increased LGR compared to those in the control group, indicating a stimulating effect on bone growth.

Furthermore, ipamorelin demonstrated a similar dose-dependent effect on body weight gain among the treated rats. Those receiving ipamorelin experienced greater increases in body weight compared to the control group.

Interestingly, despite the effects on bone growth and body weight, ipamorelin did not influence certain key markers related to growth and bone metabolism. Total IGF-I levels, IGFBPs (Insulin-like Growth Factor Binding Proteins), and serum markers of bone formation and resorption remained unaffected by ipamorelin treatment. 2

Additionally, the study examined the response of the pituitary gland to ipamorelin administration. It was observed that the plasma GH response showed a marginal reduction after ipamorelin injection, indicating a potential feedback mechanism in the regulation of GH release. However, the pituitary GH content itself remained unchanged following ipamorelin treatment. 2

Overall, the findings suggest that ipamorelin has significant effects on bone growth rate and body weight gain in adult female rats, mediated through its GH-releasing properties. Further investigation into the potential therapeutic applications of ipamorelin, particularly in the context of growth retardation, may be warranted based on these results. 2

Therapeutic Implications of Using CJC-1295 and Ipamorelin Together

The combined administration of CJC-1295 with DAC and Ipamorelin in animal studies has shown promising therapeutic implications across various physiological and pathological conditions.

Enhanced Growth Hormone Secretion: Animal studies have demonstrated that the combination of CJC-1295 with DAC and Ipamorelin leads to a synergistic increase in growth hormone (GH) secretion compared to either peptide alone. This enhanced GH secretion may have therapeutic implications for conditions characterized by GH deficiency or impaired GH secretion.
Muscle Growth and Repair: Preclinical studies in animal models have shown that the combined use of CJC-1295 with DAC and Ipamorelin can promote muscle growth and repair. By stimulating GH secretion, these peptides may enhance muscle protein synthesis and muscle hypertrophy.
Bone Health and Density: Animal research suggests that the synergistic effects of CJC-1295 with DAC and Ipamorelin may have beneficial effects on bone health and density. GH plays a crucial role in bone metabolism and maintenance of bone density, and the combination of these peptides may promote bone formation, reduce bone resorption, and improve overall bone health in animal models.
Metabolic Disorders: Animal studies have indicated that the combined use of CJC-1295 with DAC and Ipamorelin may have therapeutic implications for metabolic disorders such as obesity, insulin resistance, and metabolic syndrome. GH secretion influences various metabolic processes, including lipid metabolism, glucose homeostasis, and energy expenditure.
Wound Healing and Tissue Repair: Animal research suggests that the combination of CJC-1295 with DAC and Ipamorelin may accelerate wound healing and promote tissue repair. GH and its downstream effector insulin-like growth factor 1 (IGF-1) play critical roles in wound healing processes, including cell proliferation, collagen synthesis, and angiogenesis. Therefore, the synergistic effects of these peptides may enhance wound healing and tissue regeneration in animal models of injury or trauma.
Neuroprotection and Cognitive Function: Animal studies have indicated that the combined use of CJC-1295 with DAC and Ipamorelin may have neuroprotective effects and enhance cognitive function. GH and IGF-1 are known to exert neuroprotective effects and promote neuronal survival, synaptic plasticity, and cognitive function. Therefore, the synergistic effects of these peptides may protect neurons from damage and improve cognitive function in animal models of neurodegenerative disorders or cognitive impairment.
Animal studies suggest that the combined administration of CJC-1295 with DAC and Ipamorelin may have synergistic effects on growth hormone secretion and offer therapeutic benefits across various physiological and pathological conditions, including muscle growth and repair, bone health, metabolic disorders, wound healing, tissue repair, and neuroprotection. Further preclinical research is needed to elucidate the mechanisms underlying these effects and optimize the therapeutic use of these peptides in animal models.

Buy CJC 1295 Ipamorelin Online at Paradigm Peptides

At Paradigm Peptides, we provide top quality peptides, SARMs, and research products. Our peptides, including CJC 1295 Ipamorelin, are all pharmaceutical grade. If you have any other questions, feel free to contact us through our fantastic customer service today!

*Disclaimer: The CJC 1295 and Ipamorelin Blend currently listed on this site is sold for research use only. Not for human consumption. This product is not a drug, supplement, food or cosmetic and it may not be misused, sold, labeled or branded as such